Celgene acquires Acetylon, spins out Regenacy
The Celgene-Acetylon deal is back from the dead, seven months after the initial option agreement lapsed. Celgene is not all-in, however, which means Acetylon's pipeline will now be split into two.
HDAC inhibitors